Sickle cell patients often face challenges when implementing their care plans. Columnist Mary Shaniqua describes what good ...
Nearly all the patients with severe SCD treated with the gene-editing therapy reni-cel remained free of VOEs for up to two ...
Data from a Phase 2/3 trial shows etavopivat may reduce the incidence of vaso-occlusive crises and raise levels of hemoglobin ...
When a sickle cell pain crisis landed her in the hospital, columnist Mary Shaniqua soon identified the cause: getting two vaccines at once.
Most people with sickle cell disease (SCD) who received the gene-editing therapy Casgevy (exagamglogene autotemcel) in clinical trials have been free from vaso-occlusive crises (VOCs) over several ...